How the right embraced psychedelics

The Trump administration's sudden push to legalize Ibogaine—a powerful psychedelic derived from a West African shrub—marks a seismic shift in U.S. drug policy, especially coming from a traditionally conservative political base. Once the domain of countercultural movements, psychedelics are now being championed by right-wing veterans, former special forces operatives, and influential figures like Joe Rogan, who leveraged his platform to directly influence Trump’s executive order. The order fast-tracks research, expands 'right to try' laws to psychedelics, and allocates $50 million for state-led trials—most focused on Ibogaine’s potential to treat opioid addiction and PTSD in veterans, where suicide rates exceed battlefield deaths. While anecdotal success stories from veterans are compelling, the drug carries serious cardiac risks, with fatalities reported even in clinical settings. Despite limited scientific evidence and a history of regulatory roadblocks due to safety concerns, the political momentum is building. Journalist Maytha Busby, who experienced Ibogaine firsthand, describes it as a harrowing yet transformative journey that connected her to her father before his death—though she also witnessed a fatality at the same clinic. The episode reveals a growing tension between urgent humanitarian claims and the need for rigorous, ethical research, suggesting that the psychedelic revolution may be less about mind-expansion and more about political reinvention.